Phuong Tran
Psychiatric/Mental Health · Irvine, CANPI 1275990111
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,308 of the $26,571 with a category attached, or 61.4%. 33 manufacturers reported payments, led by Ironshore Pharmaceuticals Inc. at 45.0% of the total. Reporting peaked in 2021 at $9,637 and has fallen 96.0% since, to $387 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 530 payments — averaging $50.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$12K
- AbbVie$8K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$950
- Alkermes, Inc.$716
- Otsuka America Pharmaceutical, Inc.$434
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$16,30861%
- Travel & lodging$5372%
- Food & beverage$9,68036%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 98 | $11,968 |
| AbbVie(2 entities) | 130 | $8,246 |
| Johnson & Johnson | 54 | $1,439 |
| Teva Pharmaceuticals USA, Inc. | 72 | $950 |
| Alkermes, Inc. | 24 | $716 |
| Otsuka America Pharmaceutical, Inc. | 22 | $434 |
| Neurocrine Biosciences, Inc. | 16 | $415 |
| Supernus Pharmaceuticals, Inc. | 17 | $328 |
| Sunovion Pharmaceuticals Inc. | 20 | $292 |
| Eisai Inc. | 11 | $263 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $224 |
| Lundbeck LLC | 10 | $186 |
| Adlon Therapeutics L.p. | 12 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $141 |
| Sage Therapeutics, LLC | 1 | $133 |
| Sumitomo Pharma America, Inc. | 3 | $81 |
| Bausch Health US, LLC | 4 | $80 |
| Indivior Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Alpha Cognition USA, Inc. | 1 | $52 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $36 |
| Tris Pharma Inc | 2 | $35 |
| Merck | 2 | $35 |
| Acadia Pharmaceuticals Inc | 2 | $35 |
| Corium, LLC | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Brainsway USA Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$10,467
- VRAYLAR$6,450
- LYBALVI$460
- ARISTADA$403
- INGREZZA$250
- CAPLYTA$129
- Dayvigo$125
- INVEGA SUSTENNA$124
- INVEGA TRINZA$124
- AUSTEDO$123
- REXULTI$121
- ARISTADA INITIO$101
How this compares
$26,571 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $92,494 |
| VraylarCariprazine Hcl | 35 | $90,935 |
| Austedo XrDeutetrabenazine | 14 | $66,467 |
| NuplazidPimavanserin Tartrate | 12 | $61,177 |
| TrintellixVortioxetine Hydrobromide | 60 | $30,986 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $9,531 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $6,255 |
| Vilazodone Hcl | 44 | $5,290 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $4,160 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 29 | $3,711 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $3,405 |
| Lurasidone Hcl | 33 | $2,768 |
| Lisdexamfetamine Dimesylate | 13 | $2,679 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 80 | $2,554 |
| Mirtazapine | 89 | $1,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Namzaric | $8,246 | $97,19046 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $415 | $92,49412 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $950 | $66,46714 claims |
| Acadia Pharmaceuticals IncNuplazid | $35 | $61,17712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $141 | $40,51880 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Irvine
- Dylan GuineyIrvine$25K
- Jada AlstonIrvine$18K
- Maria AcevedoIrvine$15K
- Salina LumIrvine$15K
- Sylvia GuthrieIrvine$14K
- Farhad NikooIrvine$14K
- Kelly EguchiIrvine$12K
- Michelle NguyenIrvine$11K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.